Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632095 | 0.82 | AAK1 (0.36) | CTSLAAK1KLK5HDAC4HDAC1 | |
| SCHEMBL2113574 | 0.82 | AAK1 (0.36) | CTSLAAK1KLK5HDAC4HDAC1 | |
| SCHEMBL2632142 | 0.70 | ELANE (0.36) | CTSLKLK5CTSK | |
| SCHEMBL2117952 | 0.69 | REN (0.33) | — | |
| SCHEMBL2115282 | 0.69 | XIAP (0.40) | — | |
| SCHEMBL2117956 | 0.68 | XIAP (0.30) | — | |
| SCHEMBL2622110 | 0.68 | AAK1 (0.35) | CTSLAAK1KLK5HDAC4HDAC1 | |
| SCHEMBL2113517 | 0.68 | AAK1 (0.35) | CTSLAAK1KLK5HDAC4HDAC1 | |
| SCHEMBL10072209 | 0.68 | EPHX1 (0.46) | CTSLAAK1HDAC4HDAC1HDAC6 | |
| SCHEMBL23845229 | 0.67 | KLK5 (0.49) | CTSLAAK1KLK5HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | CTSL 134/4885AAK1 1640/4885KLK5 2327/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | CTSL 134/4885AAK1 1640/4885KLK5 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.